Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 14/20 | 0.68 |
| ▸ | MMP2 | P08253 | 3/20 | 0.63 |
| ▸ | MMP9 | P14780 | 2/20 | 0.63 |
| ▸ | MMP3 | P08254 | 1/20 | 0.52 |
| ▸ | MMP7 | P09237 | 1/20 | 0.52 |
| ▸ | MMP10 | P09238 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488443 | 0.89 | MMP2 (0.80) | ADAM17MMP2MMP9MMP3MMP7 | |
| SCHEMBL6490482 | 0.87 | ADAM17 (0.68) | ADAM17MMP2MMP9MMP3MMP7 | |
| SCHEMBL6488992 | 0.87 | ADAM17 (0.68) | ADAM17MMP2MMP9MMP3MMP7 | |
| SCHEMBL6489496 | 0.87 | ADAM17 (0.68) | ADAM17MMP2MMP9MMP3MMP7 | |
| SCHEMBL6491467 | 0.87 | ADAM17 (0.69) | ADAM17MMP2MMP9MMP3MMP7 | |
| SCHEMBL6491540 | 0.84 | MMP2 (0.62) | ADAM17MMP2MMP9MMP3MMP7 | |
| SCHEMBL6796124 | 0.83 | ADAM17 (0.86) | ADAM17MMP3MMP7MMP10 | |
| SCHEMBL6279181 | 0.83 | ADAM17 (0.80) | ADAM17MMP3MMP7MMP10 | |
| SCHEMBL6259432 | 0.83 | ADAM17 (0.80) | ADAM17MMP3MMP7MMP10 | |
| SCHEMBL6259435 | 0.83 | ADAM17 (0.80) | ADAM17MMP3MMP7MMP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004060212-A1 | ANTI-INFLAMMATORY COATING FOR IMPLANTABLE MEDICAL DEVICES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-22 | — | — | WO | claimed |
| US-20040132693-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2004-07-08 | — | — | US | claimed |
| US-20040120977-A1 | Anti-inflammatory coatings for implantable medical devices and devices containing said coatings | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | claimed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | claimed |
| US-20030225054-A1 | Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-04 | — | — | US | claimed |
| US-20030087882-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-08 | — | — | US | claimed |
| US-6962938-B2 | Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| WO-2004060212-A1 | ANTI-INFLAMMATORY COATING FOR IMPLANTABLE MEDICAL DEVICES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040132693-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2004-07-08 | — | — | US | disclosed |
| US-20040120977-A1 | Anti-inflammatory coatings for implantable medical devices and devices containing said coatings | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | disclosed |
| US-20030225054-A1 | Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-20030087882-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087882-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | ADAM17, ADAM9, TIMP3 | ADAM17 1/4885MMP2 12/4885MMP9 4/4885 |
| US-20030225054-A1 | Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents | TNF, PTGS1, MIF | ADAM17 64/4885MMP2 46/4885MMP9 40/4885 |
| US-20040132693-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | ADAM17, ADAM9, TIMP3 | ADAM17 1/4885MMP2 12/4885MMP9 4/4885 |
| US-20040120977-A1 | Anti-inflammatory coatings for implantable medical devices and devices containing said coatings | TNF, MIF, MMP12 | ADAM17 13/4885MMP2 53/4885MMP9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.